Paroxysmal Atrial Fibrillation Registry

The RACE V is an investigator-initiated, prospective, multicentre registry aiming to include 750 patients in multiple centres in The Netherlands. A total of 202 patients were included in five centres for the current interim analysis between June 2016 and December 2017. Inclusion criteria included patients aged >18 years with paroxysmal AF; a maximum history of 10 years since diagnosis at the moment of inclusion; a maximum CHA₂DS₂-VASc score of 5; and no other indication for anticoagulation drugs (e.g. mechanical valve prosthesis). Patients had to have at least two documented episodes of paroxysmal AF in the past year or one documented episode combined with at least two symptomatic episodes in the past year suspected to be AF. In patients with a Medtronic Advisa^® pacemaker, atrial high rate episodes (AHRE) >190 beats per minute lasting >6 min were qualified as AF episodes. Patients with other types of pacemakers, defibrillators, or cardiac resynchronization therapy could not participate due to differences in AHRE algorithm or incompatibility with the type of home-monitoring. Patients with a history of persistent AF, currently treated with amiodarone, current pregnancy, or a life expectancy <2.5 years were not eligible to participate. Patients with AF caused exclusively by transient triggers (e.g. post-operative, due to infection) could also not participate, as well as patients with a previous pulmonary vein isolation (PVI), or intention to undergo PVI. The study was performed in concordance with the Declaration of Helsinki. The Institutional Review Board approved the protocol, and the study was registered at Clinicaltrials.gov (identifier NCT02726698). All centres approved the protocol and all patients gave written informed consent. Intended total follow-up duration is 2.5 years.

Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link: Access Free Full Text.

De With R.R., Erküner Ö., Rienstra M., Nguyen B.O., Körver F.W., Linz D., Cate Ten H., Spronk H., Kroon A.A., Maass A.H., Blaauw Y., Tieleman R.G., Hemels M.E., de Groot J.R., Elvan A., de Melis M., Scheerder C.O., Al-Jazairi M.I., Schotten U., Luermans J.G., Crijns H.J, & Van Gelder I.C. (2020). Temporal patterns and short-term progression of paroxysmal atrial fibrillation: data from RACE V. Europace, 22(8), 1162-1172.

Publication 2020

Amiodarone Atrial Cardiac resynchronization therapy Defibrillators Diagnosis Drugs Infection Institutional review board Isolation Isolation patients Pacemakers Paroxysmal af Patients Pregnancy Prosthesis Pulmonary vein Transient Triggers

Corresponding Organization : University Medical Center Groningen

Other organizations : Maastricht University Medical Centre, Maastricht University, Martini Ziekenhuis, Rijnstate Hospital, Radboud University Nijmegen, Radboud University Medical Center, University of Amsterdam, Isala, Medtronic (Netherlands), Bakken Museum

Top 5 similar protocols

Protocol cited in 6 other protocols

Variable analysis

independent variables

None explicitly mentioned

dependent variables

Inclusion of 750 patients in multiple centers in the Netherlands
Number of patients included in the current interim analysis (202 patients in five centers)

control variables

Patients aged >18 years with paroxysmal AF
Maximum history of 10 years since diagnosis at the moment of inclusion
Maximum CHA2DS2-VASc score of 5
No other indication for anticoagulation drugs (e.g. mechanical valve prosthesis)
At least two documented episodes of paroxysmal AF in the past year or one documented episode combined with at least two symptomatic episodes in the past year suspected to be AF
Patients with a Medtronic Advisa® pacemaker, where atrial high rate episodes (AHRE) >190 beats per minute lasting >6 min were qualified as AF episodes
Patients with other types of pacemakers, defibrillators, or cardiac resynchronization therapy could not participate due to differences in AHRE algorithm or incompatibility with the type of home-monitoring
Patients with a history of persistent AF, currently treated with amiodarone, current pregnancy, or a life expectancy <2.5 years were not eligible to participate
Patients with AF caused exclusively by transient triggers (e.g. post-operative, due to infection) could also not participate
Patients with a previous pulmonary vein isolation (PVI), or intention to undergo PVI could not participate

controls

None explicitly mentioned

Annotations

Based on most similar protocols

Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.

As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!